financetom
Business
financetom
/
Business
/
Eastman Kodak Q2 revenue down 1%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eastman Kodak Q2 revenue down 1%
Aug 11, 2025 1:50 PM

Overview

* Kodak Q2 revenue declines 1% yr/yr to $263 mln

* GAAP net loss of $26 mln vs. net income of $26 mln in Q2 2024

* Operational EBITDA falls 25% to $9 mln due to higher costs

* Substantial doubt raised about Kodak's ability to continue operations

Outlook

* Kodak plans to focus on serving customers and developing growth businesses in H2 2025

* Company assessing potential impact of new tariffs on future business

* Kodak committed to U.S. manufacturing despite uncertain business environment

* Kodak plans to reduce costs and convert investments into long-term growth in H2 2025

Result Drivers

* HIGHER COSTS - Operational EBITDA impacted by increased aluminum and manufacturing costs, partially offset by price increases

* AM&C GROWTH - Advanced Materials & Chemicals segment sees revenue growth, with FDA certification for pharmaceutical manufacturing

* CASH FLOW CHALLENGES - Cash balance reduced due to capital expenditures and higher operational costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $263 mln

Revenue

Q2 Net -$26 mln

Income

Q2 $9 mln

Operatio

nal

EBITDA

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amgen Launches Two Phase 3 Trials for Obesity Drug MariTide
Amgen Launches Two Phase 3 Trials for Obesity Drug MariTide
Mar 5, 2025
11:25 AM EST, 03/05/2025 (MT Newswires) -- Amgen ( AMGN ) has initiated two phase 3 trials for its obesity drug MariTide, the company's Head of Research and Development, Jay Bradner, said Wednesday at an investor conference. One of the trials is in people with obesity or overweight without type 2 diabetes, and is expected to enroll 3,500 people, Bradner...
Market Chatter: Goldman Sachs, JPMorgan Offering Russia-Linked Trades
Market Chatter: Goldman Sachs, JPMorgan Offering Russia-Linked Trades
Mar 5, 2025
11:17 AM EST, 03/05/2025 (MT Newswires) -- Goldman Sachs ( GS ) and JPMorgan Chase ( JPM ) are facilitating investor interest in Russian-related assets by offering ruble-linked derivative contracts, Bloomberg News reported Wednesday, citing people familiar with the matter. These contracts, called non-deliverable forwards, or NDFs, allow traders to profit from a surge in the ruble's value without directly...
Pluri, Hemafund Sign Exclusive Collaboration Deal on Potential Radiation Treatment; Shares Rise
Pluri, Hemafund Sign Exclusive Collaboration Deal on Potential Radiation Treatment; Shares Rise
Mar 5, 2025
11:23 AM EST, 03/05/2025 (MT Newswires) -- Pluri ( PLUR ) said Wednesday that it signed an exclusive collaboration deal with Hemafund, an umbilical cord blood bank, for the distribution and clinical advancement of PLX-R18 cell therapy as a potential treatment for Hematopoietic Acute Radiation Syndrome in Ukraine. Pluri ( PLUR ) said it has agreed to produce and supply...
Kenvue Reaches Accord With Activist Investor Starboard Value, Adds 3 New Board Members
Kenvue Reaches Accord With Activist Investor Starboard Value, Adds 3 New Board Members
Mar 5, 2025
11:21 AM EST, 03/05/2025 (MT Newswires) -- Kenvue ( KVUE ) on Wednesday named three new members to its board as part of a cooperation agreement with activist investor Starboard Value. Under the agreement, Starboard will withdraw its slate of nominated director candidates and vote all of its shares in favor of Kenvue ( KVUE ) board nominees, the companies...
Copyright 2023-2026 - www.financetom.com All Rights Reserved